Flagship Ventures’ David Berry Named Technology Review’s Top Young Innovator

Flagship Ventures’ David Berry Named Technology Review’s Top Young Innovator

August 15, 2007

First Innovator of the Year from Venture Industry

Cambridge, MA – August 15, 2007 – Flagship Ventures today announced that Dr. David A. Berry, a Principal at the firm, has been recognized by MIT’s Technology Review magazine as Innovator of the Year in its 2007 TR35 list of world’s top 35 innovators under the age of 35. Dr. Berry is being honored for his contributions to the founding of LS9, Inc., a biotechnology company which uses synthetic biology to design microorganisms that can produce hydrocarbon biofuels. The Innovator of the Year was selected by a panel of expert judges and the editorial staff of Technology Review from more than 300 nominees for the TR35, an elite group of accomplished young innovators who exemplify the spirit of innovation in business, technology and the arts. The 2007 winners will be honored at Technology Review’s Emerging Technologies Conference at MIT on Wednesday, September 26th.
“We congratulate David on his award and accomplishments, and take pride in his being the first Innovator of the Year selected from the Venture industry,” commented Noubar Afeyan Ph.D., Managing Partner and CEO of Flagship Ventures and Chairman of LS9. “David’s work with LS9 is a wonderful example of the venture creation work we have been pursuing here at Flagship for several years now. LS9 is among the most recent new ventures in a line of fifteen Flagship startups including Adnexus Therapeutics, Affinnova, BG Medicine, Codon Devices, Ensemble Discovery and Helicos Biosciences. We are already hard at work on our next set of startups which include improved cancer treatments, new drug targeting mechanisms, as well as clean and sustainable energy solutions. We look forward to not only our new ventures team’s and the companies’ future successes, but also the positive contributions that they bring to society.”

“I’m truly honored to receive this award,” said David Berry, M.D., Ph.D, Principal, Flagship Ventures. “The success of LS9 is really the result of an outstanding team of innovative people from academia and industry working together in a pioneering entrepreneurial effort. In a short time, we have been able to develop and protect through extensive patent filings, an entirely new approach to renewable energy, one that applies synthetic biology to produce efficient, hydrocarbon producing microorganisms. This innovation promises to offer the first source of Renewable PetroleumTM products with potential to significantly impact the world”.

“The TR35 Innovator of the Year award honors one of the world’s top young innovators for accomplishments that are poised to have a dramatic impact on the world,” said Jason Pontin, Editor in Chief and Publisher of Technology Review magazine. “We celebrate Dr. Berry’s success and look forward to his continued contribution to technology and life sciences."

David Berry and the other TR35 winners for 2007 will be featured in the September issue of Technology Review magazine. Additional information about past and present TR35 winners and judges is available at www.technologyreview.com/tr35/. For more information about Technology Review's 2007 Emerging Technologies Conference, please visit: http://www.technologyreview.com/events/tretc/index.aspx.

About David Berry, M.D., Ph.D.

David Berry is a Principal at Flagship Ventures. He joined Flagship in 2005 while completing his M.D. from Harvard Medical School. David was previously awarded a Ph.D. through the MIT Biological Engineering Division, where his advisors were Professors Ram Sasisekharan and Robert Langer. At MIT, David studied the biological effects of glycosaminoglycans and applied his work to develop new potential therapeutics for stroke and cancer. His work led to ten peer-reviewed papers, ten patents and over twenty awards and honors, including the prestigious Lemelson-MIT Student Prize in 2005 for invention and innovation. David also did his undergraduate work at MIT, graduating in 2000 Phi Beta Kappa and Sigma Xi, with a degree in brain and cognitive sciences. He was named a member of the MIT Corporation - its Board of Trustees - in 2006. At Flagship, David focuses on early stage life science and cleantech ventures and works closely with portfolio companies BG Medicine, T2 Biosystems, Epitome Biosystems in addition to LS9.

About Flagship Ventures

Flagship Ventures is a leading venture capital firm focused on creating, financing, and building innovative companies. Founded in 2000, Flagship operates from its offices at Kendall Square in Cambridge, MA. With an active portfolio of over 40 companies, the firm’s strategy is to balance its investments across three principal business sectors: Life Science / Diagnostics Tools, Energy & Technology Platforms, and Therapeutics. Through its unique venture creation and seed investing programs, Flagship actively participates in developing new ventures that are commercializing many of the leading breakthroughs of our times. Prior to its founding, Flagship's principals were involved as founders or investors in over 100 firms including: Aspect Medical, Celera Genomics, ChemGenics Pharmaceuticals, Color Kinetics, Cytyc, DataSage, IDEXX, PerSeptive Biosystems, and TripAdvisor. For more information, visit www.flagshipventures.com.

About Technology Review, Inc.

Technology Review, Inc., an independent media company owned by MIT, is the authority on the future of technology, identifying emerging technologies and analyzing their impact for leaders. Technology Review's media properties include Technology Review magazine, the oldest technology magazine in the world (founded in 1899); the daily news website TechnologyReview.com; and events such as the annual Emerging Technologies Conference at MIT.


For Flagship Ventures

Bill Koteff, 617-218-1613

For Technology Review

Kathryn Ghita, 617-682-3792
KMC Partners Public Relations
One Broadway, 5th Floor
Cambridge, MA 02142